This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

This study has been completed.
Kantonsspital Aarau
Information provided by (Responsible Party):
Peter Moosmann, Kantonsspital Aarau Identifier:
First received: January 24, 2007
Last updated: April 2, 2015
Last verified: April 2015
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Condition Intervention Phase
Lymphoma, Non-Hodgkin Drug: Bendamustine Drug: Bortezomib Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study

Resource links provided by NLM:

Further study details as provided by Peter Moosmann, Kantonsspital Aarau:

Primary Outcome Measures:
  • Optimal Bendamustine Dosage for Further Studies [ Time Frame: Three weeks after treatment termination ]

Enrollment: 12
Study Start Date: January 2007
Study Completion Date: June 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bendamustine and Bortezomib
Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
Drug: Bendamustine
starting with 60 mg/m^ 2, IV, dose escalation, weekly d1,8,15 q5w
Other Name: Ribomustin, SDX-105
Drug: Bortezomib
weekly 1.5mg/m^2, IV, d1,8,15,22 q5w
Other Name: Velcade

Detailed Description:

Bendamustin and bortezomib have been shown to be effective in the treatment of patients with indolent Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Both compounds appear not to be cross-resistant with prior therapy. Therefore, it is of interest to combine bendamustine and bortezomib in this patient population.

Preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated. However, there are so far no data on this combination in patients with NHL or CLL.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Symptomatic recurrent or refractory indolent NHL or B-CLL
  • Adequate organ and bone marrow function
  • Karnofsky greater than 50%

Exclusion Criteria:

  • Candidates for autologous stem cell transplantation
  • Secondary high grade lymphoma
  • Concurrent severe medical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00426855

Sponsors and Collaborators
Peter Moosmann
Kantonsspital Aarau
Principal Investigator: Peter R Moosmann, MD PhD Cantonal Hospital of Aarau, Switzerland
  More Information

Responsible Party: Peter Moosmann, MD PhD, Kantonsspital Aarau Identifier: NCT00426855     History of Changes
Other Study ID Numbers: ZOHT-01/07
Study First Received: January 24, 2007
Results First Received: June 27, 2011
Last Updated: April 2, 2015

Keywords provided by Peter Moosmann, Kantonsspital Aarau:
Lymphoma, Non-Hodgkin, Low-Grade

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Bendamustine Hydrochloride
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017